Key result
The Medtronic 5086 MRI pacing lead was associated with a higher 30-day rate of pericarditis, effusion, tamponade, or death compared to the 5076 lead.
Why the study?
Does the MR-conditional Medtronic 5086 pacing lead increase the risk of early lead-related complications compared to the previous generation 5076 lead in patients undergoing pacemaker implantation?
Case-Control (n=157)
No
Does the MR-conditional Medtronic 5086 pacing lead increase the risk of early lead-related complications compared to the previous generation 5076 lead in patients undergoing pacemaker implantation?
The newer MR-conditional Medtronic 5086 pacing lead is associated with a significantly higher risk of early major complications and lead dislodgement compared to the older 5076 lead.
Answers are grounded in this paper and cite their sources.
May warrant caution with the 5086 lead; leaves open need for larger studies on MR-conditional lead safety.
OBJECTIVE: The purpose of our study was to determine if the rate of lead-related complications was increased with the Medtronic CapSureFix MRI™ SureScan™ 5086 MRI pacing lead (5086; Medtronic Inc., Minneapolis, MN, USA) compared to the previous generation of Medtronic CapSureFix Novus™ 5076 pacing lead (5076). BACKGROUND: The 5086 lead is a newly introduced active-fixation pacemaker lead designed to be used conditionally in a magnetic resonance (MR) scanner. This lead has specific design changes compared to the previous generation of 5076 pacing leads. METHODS: This study was a retrospective case control study of 65 consecutive patients implanted with two 5086 leads compared to 92 consecutive control patients implanted with two 5076 leads over a 14-month period at a high-volume tertiary care hospital. RESULTS: Pericarditis, pericardial effusion, cardiac tamponade, or death within 30 days of implant were seen in eight patients from the 5086 cohort and two from the 5076 cohort (odds ratio 6.3, 95% confidence interval 1.3-30.8, P = 0.02). Lead dislodgement occurred in four of the 5086 patients and in none of the 5076 patients (P < 0.03). CONCLUSIONS: In a high-volume center, the incidence of pericarditis, cardiac perforation, tamponade, death, and lead dislodgement was significantly higher with the MR-conditional Medtronic 5086 lead when compared to the previous generation Medtronic 5076 lead.
No takes yet. Share an insight, caveat, or question.
Elmouchi et al. (2013) conducted a case-control in Pacemaker implantation (n=157). Medtronic CapSureFix MRI SureScan 5086 MRI pacing lead vs. Medtronic CapSureFix Novus 5076 pacing lead was evaluated on Pericarditis, pericardial effusion, cardiac tamponade, or death within 30 days of implant (OR 6.3, 95% CI 1.3-30.8, p=0.02). The Medtronic 5086 MRI pacing lead was associated with a higher 30-day rate of pericarditis, effusion, tamponade, or death compared to the 5076 lead.
Synapse has enriched 10 related papers. Consider them for comparative context: